• 1. Evolved polymerases facilitate selection of fully 2′-OMe-modified aptamers?
  Zhixia Liu,Tingjian Chen,Floyd E. Romesberg Chem. Sci., 2017,8, 8179-8182
• 2. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389
• 3. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084
• 4. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 5. Evolution in surface coverage of CH3NH3PbI3?XClXvia heat assisted solvent vapour treatment and their effects on photovoltaic performance of devices
  Dhirendra K. Chaudhary,Pramendra Kumar,Lokendra Kumar RSC Adv., 2016,6, 94731-94738

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzoic acids and derivatives Halobenzoic acids and derivatives

Recent Advances in the Study of 2-Bromo-5-propoxybenzoic Acid (CAS: 190965-43-6) in Chemical Biology and Pharmaceutical Research

2-Bromo-5-propoxybenzoic acid (CAS: 190965-43-6) has emerged as a compound of significant interest in chemical biology and pharmaceutical research due to its versatile applications in drug discovery and development. Recent studies have highlighted its potential as a key intermediate in the synthesis of bioactive molecules, particularly in the design of novel anti-inflammatory and anticancer agents. This research brief aims to provide an overview of the latest findings related to this compound, focusing on its synthesis, biological activities, and potential therapeutic applications.

The synthesis of 2-Bromo-5-propoxybenzoic acid has been optimized in recent studies to improve yield and purity, which are critical for its application in pharmaceutical formulations. Researchers have employed advanced catalytic methods and green chemistry principles to achieve these improvements. For instance, a 2023 study demonstrated the use of palladium-catalyzed cross-coupling reactions to enhance the efficiency of bromination and propoxylation steps, resulting in a higher yield of the target compound. These advancements are expected to facilitate its broader use in medicinal chemistry.

In terms of biological activity, 2-Bromo-5-propoxybenzoic acid has shown promising results in preclinical studies. A recent investigation revealed its ability to modulate key inflammatory pathways by inhibiting the production of pro-inflammatory cytokines such as TNF-α and IL-6. This anti-inflammatory effect was observed in both in vitro and in vivo models, suggesting its potential as a lead compound for developing new anti-inflammatory drugs. Additionally, preliminary data from another study indicated that derivatives of this compound exhibit selective cytotoxicity against certain cancer cell lines, opening new avenues for anticancer drug development.

The mechanistic studies of 2-Bromo-5-propoxybenzoic acid have also provided valuable insights into its mode of action. Structural-activity relationship (SAR) analyses have identified the bromo and propoxy substituents as critical for its bioactivity. Molecular docking simulations have further elucidated its interactions with target proteins, such as cyclooxygenase-2 (COX-2) and nuclear factor-kappa B (NF-κB), which are implicated in inflammation and cancer. These findings underscore the compound's potential as a scaffold for designing more potent and selective inhibitors.

Despite these promising developments, challenges remain in the clinical translation of 2-Bromo-5-propoxybenzoic acid and its derivatives. Issues such as bioavailability, metabolic stability, and potential toxicity need to be addressed through further research. Recent efforts have focused on optimizing the pharmacokinetic properties of this compound by modifying its chemical structure or formulating it as a prodrug. Collaborative studies between academic and industrial researchers are expected to accelerate the translation of these findings into clinically viable therapeutics.

In conclusion, 2-Bromo-5-propoxybenzoic acid (CAS: 190965-43-6) represents a promising candidate for drug development, with demonstrated anti-inflammatory and anticancer activities. The latest research has advanced our understanding of its synthesis, biological effects, and mechanistic underpinnings, paving the way for future applications. Continued exploration of this compound and its derivatives is likely to yield novel therapeutic agents with significant clinical impact.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)